| Chronic Kidney Disease |
1 |
1 |
| Renal Failure |
0 |
0.99 |
| Type 2 Diabetes Mellitus |
0 |
0.97 |
| GLP-1 Receptor Agonist |
0 |
0.7 |
| Renal Disease |
0 |
0.52 |
| Kidney |
0 |
0.46 |
| Receptors |
0 |
0.46 |
| SGLT2 Inhibitor |
0 |
0.46 |
| Angiotensin II Receptor Blockade |
0 |
0.38 |
| Lipids Management |
0 |
0.33 |
| Type 1 Diabetes Mellitus |
0 |
0.26 |
| Hypertension |
0 |
0.21 |
| Clinical Guidelines |
0 |
0.2 |
| Drug Costs |
0 |
0.13 |
| PCSK9 |
0 |
0.13 |
| Preventive Screening |
0 |
0.13 |
| Stress |
0 |
0.13 |
| Cardiovascular Risk Management |
0 |
0.09 |
| Coronary Artery Disease (CAD) |
0 |
0.09 |
| Health Insurance |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| ACE Inhibitor |
0 |
0.07 |
| Antiplatelet Agent |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.07 |
| Diet |
0 |
0.07 |
| Exercise |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Medicare |
0 |
0.07 |
| Prediabetes |
0 |
0.07 |
| Renin-Angiotensin System |
0 |
0.07 |
| Statins |
0 |
0.07 |
| Washington |
0 |
0.07 |
| COVID-19 |
0 |
0.06 |